MG
ABCL icon

Michael Gelband’s AbCellera Biologics ABCL Stock Holding History

Michael Gelband’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.87M Buy
237,952
+95,206
+67% +$465K 0.01% 846
2026
Q1 		$498K Buy
142,746
+29,678
+26% +$107K ﹤0.01% 1191
2025
Q4 		$387K Buy
+113,068
New +$505K ﹤0.01% 1246
2025
Q1 		– Sell
-281,795
Closed -$826K – 1396
2024
Q4 		$826K Buy
+281,795
New +$785K 0.01% 1003
2024
Q2 		– Sell
-496,012
Closed -$2.25M – 1461
2024
Q1 		$2.25M Buy
496,012
+362,358
+271% +$1.85M 0.02% 652
2023
Q4 		$763K Buy
+133,654
New +$619K 0.01% 910
2023
Q3 		– Sell
-214,557
Closed -$1.39M – 1633
2023
Q2 		$1.39M Sell
214,557
-37,635
-15% -$257K 0.01% 972
2023
Q1 		$1.9M Buy
252,192
+71,842
+40% +$652K 0.02% 901
2022
Q4 		$1.83M Buy
180,350
+5,600
+3% +$64.7K 0.03% 684
2022
Q3 		$1.73M Sell
174,750
-87,753
-33% -$963K 0.02% 864
2022
Q2 		$2.8M Buy
262,503
+133,652
+104% +$1.13M 0.03% 644
2022
Q1 		$1.26M Buy
128,851
+46,026
+56% +$436K 0.02% 1016
2021
Q4 		$1.18M Buy
+82,825
New +$1.26M 0.01% 983
2021
Q3 		– Sell
-29,972
Closed -$659K – 2031
2021
Q2 		$659K Buy
29,972
+20,729
+224% +$572K 0.01% 1216
2021
Q1 		$314K Sell
9,243
-19,607
-68% -$781K ﹤0.01% 1635
2020
Q4 		$1.16M Buy
+28,850
New +$1.32M 0.01% 776

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Michael Gelband's ABCL Position: Q2 2026 in Review

Michael Gelband increased its AbCellera Biologics (ABCL) stake by 67% in Q2 2026, buying an estimated $465K and bringing the position to 237,952 shares worth $1.87M. The position accounts for 0.01% of the portfolio, ranked #846.

Michael Gelband first reported a position in ABCL in Q4 2020 and has held it in 16 quarters since. The position peaked at $2.8M in Q2 2022. 151 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Michael Gelband held 237,952 shares of AbCellera Biologics worth $1.87M as of Q2 2026.
  • Michael Gelband bought 95,206 AbCellera Biologics shares in Q2 2026, an estimated $465K.
  • AbCellera Biologics made up 0.01% of Michael Gelband's portfolio in Q2 2026, its #846 holding.
  • Michael Gelband first reported a position in AbCellera Biologics in Q4 2020 and has held it in 16 quarters since.
  • Michael Gelband's AbCellera Biologics position peaked at $2.8M in Q2 2022.
  • 151 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.